Approved for XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). Enzalutamide is an androgen receptor inhibitor that acts on different steps in the…
Loading full data from Know Your Drugs Institute…